Lung Cancer Xenograft Models Available

Lung Cancer Models

Lung cancer is the leading cause of cancer related mortality in the United States.

There are two main histologic subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer(SCLC). NSCLC is further differentiated histologically into adeno-, squamous cell, and large cell carcinomas.

Small cell tumors metastasize very early but are relatively responsive to platinum based chemotherapy (DNA damaging drugs)

Patients with metastatic squamous cell carcinoma (SCC) have fewer treatment options than those with non-squamous NSCLC. There is a need for development of SCC models to facilitate the identification of molecular targets and development targeted therapies.

Request formal project quotation from Altogen Labs CRO.

Many PDTX Lung tumor models are available:

Tumor type Mutations Comments
Squamous Cell Carcinoma TP53, EGFR(R521K), PIK3CA Sensitivity to antibody therapy (Cetuximab)
Adenocarcinoma EGFR(L858R) Increased sensitivity to TKIs1
EGFR(T790M), Exon 19 del2 Resistance to TKIs (erlotinib/gefitinib)
KRAS(G12C), KRAS(G12A) May decrease TKI sensitivity
EML4-ALK translocation Increased sensitivity to ALK/MET TKI crizotinib)

1TKI—Tyrosine Kinase Inhibitors: TKIs bind to and inhibit receptor Tyrosine kinases and suppress receptor mediated intracellular signaling. 2EGFR Exon 19 del: In-frame deletion of exon19 deleting a portion of the receptor Tyrosine kinase domain. 3NSCLC—Non-Small Cell Lung Carcinoma sensitivity to ionizing radiation.

Request lung cancer xenograft project quotation from Altogen Labs CRO.